High-Output Heart Failure and Dialysis Access
AV fistulas and AV grafts are essential for hemodialysis, but they create low-resistance vascular circuits that can increase venous return and cardiac output demand — and, in some patients, contribute to cardiac remodeling, pulmonary hypertension, and high-output heart failure.
An AV fistula or AV graft connects an artery directly to a vein, providing the reliable high flow needed for dialysis. The same anatomy that makes hemodialysis possible, however, can also impose continuous extra work on the heart. This page explains how dialysis access affects cardiac output, what symptoms patients and clinicians may notice, and how flow-control dialysis access is being discussed as a more cardiac-conscious approach.
How dialysis access affects the heart
In a healthy circulation, blood pumped from the heart passes through a high-resistance capillary bed before returning to the venous side. A surgically created AV fistula or AV graft bypasses that resistance, allowing blood to travel directly from artery to vein. The result is a sustained increase in venous return and in the volume of blood the heart must pump every minute.
This is not a transient effect during a dialysis session. The shunt is present 24 hours a day, every day, for as long as the access is in place. The cumulative cardiac burden is what distinguishes the hemodynamics of long-term dialysis access from many other clinical conditions. For more on the underlying physiology, see cardiac burden of AV fistulas and AV grafts.
High-flow AV access and high-output heart failure
High-output heart failure is a clinical state in which the heart pumps an unusually large volume of blood per minute and yet remains unable to meet the body's needs. High-flow dialysis access — high-flow AV fistulas and high-flow AV grafts — can contribute to this state by layering a continuous, non-physiologic flow load on top of any underlying cardiovascular disease.
Cardiac remodeling and pulmonary hypertension are commonly discussed in this context. Both can develop in response to sustained increases in cardiac output demand, and both can precede or accompany high-output heart failure in susceptible patients. The relationship is not deterministic — many patients tolerate dialysis access without progressing to heart failure — but the field increasingly recognizes the access circuit itself as a relevant cardiac variable.
Symptoms and clinical concerns
Several symptoms are sometimes associated with high-flow dialysis access and the cardiac burden it can create, including:
- Shortness of breath, especially with exertion or when lying flat
- Fatigue beyond what is typical for the patient
- Exercise intolerance or reduced functional capacity
- Signs of pulmonary hypertension on imaging or right-heart catheterization
- Heart-failure symptoms such as swelling in the legs or worsening overall function
These symptoms have many possible causes, including those unrelated to dialysis access, and are not by themselves diagnostic of high-output heart failure. Any new or worsening symptoms in a hemodialysis access patient warrant evaluation by a physician familiar with the patient's history. This page is informational and is not medical advice.
Why access flow matters
The volume of blood moving through an AV fistula or AV graft — the access flow — is the most direct lever on the cardiac burden created by the access. Historically, access flow has been discussed using fixed thresholds such as 1.5 to 2.0 L/min, but recent discussion in the field, including at the Vascular Access Society of the Americas (VASA), has emphasized that clinically meaningful cardiac changes may occur at considerably lower access-flow levels. The more useful frame is the physiologic effect on the patient, not the access-flow number alone.
For more on the broader category, see high-flow dialysis access.
Access flow reduction and current clinical approaches
When high-flow access is identified, clinicians may consider access flow reduction — a strategy that lowers the volume of blood moving through the access while preserving its function for dialysis. Several technical approaches exist, including surgical banding, balloon-assisted maturation reversal, and other revision procedures. These approaches are typically pursued after symptoms or complications have appeared.
Reactive access flow reduction can be effective but has limitations: it requires a separate intervention, it intervenes after some degree of cardiac burden has accumulated, and it does not change the design assumption that the access should default to maximal flow. The field has begun to consider whether controlled flow should be a property of the access itself.
Flow-control dialysis access
Flow-control dialysis access is an emerging category designed around two simultaneous goals: adequate dialysis and patient cardiac tolerance. Rather than maximizing access flow and intervening later, flow-control approaches incorporate controlled access flow into the design of the graft or stent from the start. The category includes flow-control grafts and flow-control stents.
The framing matters because it changes what the access is optimized for. In a flow-control framework, the question is not "how much flow can we get?" but "how much flow does the patient need for dialysis, and how much can the heart tolerate over time?" For more on the category, see flow-control dialysis access.
VascX and cardiac-conscious access design
VascX is developing a cardiac-conscious approach to dialysis access — a platform designed around two simultaneous goals: preserve the dialysis adequacy patients depend on, and reduce the continuous cardiac burden that excessive access flow can impose on the heart. The platform includes elastic flow-control grafts and elastic flow-control stents, intended to deliver dialysis-grade flow during treatment while limiting the between-session load that, in some patients, has been associated with cardiac remodeling, pulmonary hypertension, and high-output heart failure.
VascX products are investigational. The company does not claim that its devices are proven to treat or prevent cardiac remodeling, pulmonary hypertension, high-output heart failure, hospitalization, or mortality. The platform is designed to address the underlying physiology — access flow — that the field increasingly views as relevant to cardiac outcomes in dialysis patients.
Frequently asked questions
What is high-output heart failure in dialysis access?
High-output heart failure is a clinical state in which the heart pumps more blood per minute than usual but is still unable to meet the body's needs. In dialysis access patients, this state can develop when an AV fistula or AV graft creates a persistent high-flow vascular circuit that increases cardiac output demand. Over time, the continuous extra workload is associated with cardiac remodeling, pulmonary hypertension, and, in susceptible patients, high-output heart failure.
Can an AV fistula contribute to high-output heart failure?
In some patients, yes. An AV fistula creates a low-resistance shunt between an artery and a vein, increasing venous return and the volume of blood the heart must pump each minute. High-flow AV fistulas are associated with cardiac remodeling and pulmonary hypertension in susceptible patients, and have been discussed in the dialysis access field as a potential contributor to high-output heart failure.
Can an AV graft increase cardiac workload?
Yes. An AV graft creates the same kind of arteriovenous shunt as a fistula, diverting blood through a low-resistance pathway and increasing the cardiac output required to perfuse the rest of the body. High-flow AV grafts can contribute to the same continuous hemodynamic load and are associated with cardiac remodeling and pulmonary hypertension in some patients.
What symptoms may be associated with high-flow dialysis access?
Symptoms that may be associated with high-flow dialysis access include shortness of breath, fatigue, exercise intolerance, and signs of heart failure such as fluid retention or reduced functional capacity. These symptoms can have many causes and are not specific to high-flow access. Patients experiencing these symptoms should consult their physician for evaluation.
What is access flow reduction?
Access flow reduction is a clinical strategy that lowers the volume of blood flowing through an AV fistula or AV graft while preserving the access for hemodialysis. The goal is to reduce continuous cardiac burden imposed by excessive access flow without compromising dialysis adequacy. Historically, access flow reduction has been pursued reactively, after complications appear; flow-control dialysis access aims to make controlled flow part of the access design from the start.
What is flow-control dialysis access?
Flow-control dialysis access is an emerging category of hemodialysis access designed to deliver the blood flow needed for effective dialysis without imposing unnecessary continuous high-flow burden on the heart. Rather than treating excessive access flow only after complications appear, flow-control approaches incorporate controlled access flow into the design of the graft or stent itself.
Are VascX products FDA-cleared?
VascX products are currently in development and are not yet cleared or approved by the U.S. Food and Drug Administration.